Status:
COMPLETED
To Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Collaborating Sponsors:
Kyunghee university hospital A Drug Analytical Laboratory
Conditions:
Hypertension
Eligibility:
MALE
19-50 years
Phase:
PHASE1
Brief Summary
An Open-label, Randomized, Single-dose, 2×2 Crossover Study to Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual ...
Detailed Description
After subjects have signed informed consent voluntarily, they go through screening period for within 21 days. As period I, subjects of A Group take fimasartan and amlodipine at 1st day and subjects o...
Eligibility Criteria
Inclusion
- Healthy male subject, aged 19- 50 years at screening.
- Body weight of ≥ 50 kg and within ± 20% of ideal body weight (IBW)(kg) = {height (cm) - 100} \* 0.9
- Subjects must be able to listen to and understand the detailed statement of informed consent, and willing to decide to participate in the study, follow the study directions and provide written informed consent
Exclusion
- History of gastrointestinal disease (i.g., Crohn's disease, active peptic ulcer) or resection operation that may affect the absorption of the study drug (excluding simple appendectomy or herniorrhaphy)
- History of clinically significant hypersensitivity to study drug, any other drug or additives (yellow no.4).
- Subject that is judged inappropriate for participating in the study based on physical examination
- The levels of ALT(Aspartate Transaminase), AST (Alanin Transaminase) or total bilirubin \> 1.5 x the upper limit of normal or eGFR \< 60 mL/min/1.73m (calculated by MDRD)
- Evidence of hereditary disease, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
- systolic ≥ 140 mmHg or ≤ 100 mmHg, diastolic ≥ 90 mmHg or ≤ 65 mmHg), measured after taking a rest for 5minutes
- Take any other study's investigational products within 90 days prior to the first administration of study drug
- Donation of whole blood within 60 days prior to the first administration of study drug, or donation of any blood products within 30 days prior to the first administration of study drug
- Intake food like Grapefruit juice (\*e.g., Grapefruit juice ≥ 1L /day) within 7 days prior to administration of study drug
- Use of any prescribed drugs or herbal remedies within 14 days, or use of any over-the-counter medication or vitamins within 7 days prior to the first administration of study drug
- Positive serologic tests (HBsAg, HCV Ab, HIV Ag/Ab, VDRL)
- Subject that is judged inappropriate for participating in the study by an investigator, based any other reason
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT02205151
Start Date
July 1 2014
End Date
September 1 2014
Last Update
October 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Catholic university St. Mary hospital
Seoul, South Korea, 137-701